Elicio Therapeutics (ELTX) AI Stock Analysis

• Market Cap: $87.58M
• Dividend Yield: N/A
• Average Volume (3M): 43.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: N/A
• EPS Growth: 27.65%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 48
• Industry: Biotechnology
• EPS (TTM): -4.45
• Shares Outstanding: 15,953,524
• 10 Day Avg. Volume: 30,875
• 30 Day Avg. Volume: 43,225
• PEG Ratio: 0.24
• Price to Book (P/B): -5.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.17
• Enterprise Value/Market Cap: 1.10
• Enterprise Value/Revenue: 82.34
• Enterprise Value/Gross Profit: 331.06
• Enterprise Value/Ebitda: -0.82
• 1Y Price Target: $11.00
• Price Target Upside: 99.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Elicio Therapeutics faces significant financial challenges, with negative revenue growth and poor margins being the primary concerns. Technical analysis indicates bearish momentum, while the valuation aspect shows limited appeal. However, recent positive corporate events, such as leadership changes and clinical advancements, provide some optimism for future potential, albeit with high risk.

Positive Factors

Clinical Trials

Elicio's Phase 2 trial with 7 peptides is expected to show a clear mDFS benefit, as the Phase 1 trial with 2 peptides showed a significantly longer mRFS.

Commercialization Potential

Potential successful commercialization of ELI-002 7P across multiple solid tumor types could yield peak revenues exceeding $550M in the U.S. alone by 2035.

Regulatory Alignment

Elicio Therapeutics has reached alignment with the FDA on the registration trial in KRAS mutant pancreatic cancer.

Negative Factors

Financial Performance

Elicio Therapeutics reported a net loss of $4.25 per share—wider than previously estimated net loss of $3.62 per share.

Risks in Clinical Trials

Risks include failure to generate clear proof-of-concept clinical efficacy data showing the impact of ELI-002 7P in KRAS-mutated cancers.

Elicio Therapeutics Business Overview & Revenue Model

Company Description

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

How the Company Makes Money

Elicio Therapeutics makes money primarily through the development and commercialization of its proprietary immunotherapy products. The company generates revenue by partnering with pharmaceutical companies for the co-development and licensing of its technologies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales. Additionally, Elicio may receive funding from grants and research collaborations with academic institutions and government agencies, which contribute to its earnings.

Elicio Therapeutics Financial Statement Overview

Summary

Elicio Therapeutics is in a challenging financial position with negative revenue growth, poor margins, and reliance on external financing. The negative equity and cash flow issues highlight significant financial instability.

Income Statement

Elicio Therapeutics has faced declining revenues over the years, with no revenue reported for the latest periods. This has resulted in negative margins across the board, including gross profit, EBIT, and net income margins.

Balance Sheet

The company has negative stockholders' equity, indicating a high level of leverage and financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which is a significant concern for financial health.

Cash Flow

Elicio Therapeutics has consistently negative operating and free cash flows, indicating challenges in generating cash from its operations. The financing cash flows are positive, suggesting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	28.31M	2.88M
	Gross Profit
0.00	-1.17M	-1.06M	27.08M	1.06M
	EBIT
-44.99M	-35.74M	-23.73M	-25.47M	-15.72M
	EBITDA
-44.99M	-32.97M	-23.55M	-51.92M	-15.53M
	Net Income Common Stockholders
-51.90M	-35.20M	-28.21M	-26.40M	-15.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
17.62M	12.89M	6.16M	9.28M	14.97M
	Total Assets
28.18M	27.15M	22.66M	14.81M	19.66M
	Total Debt
26.04M	6.92M	7.48M	11.80M	439.43K
	Net Debt
8.42M	-5.98M	1.33M	2.52M	-14.53M
	Total Liabilities
39.49M	15.77M	124.81M	89.35M	68.80M
	Stockholders Equity
-11.31M	11.37M	-102.15M	-74.54M	-49.14M
Cash Flow		Free Cash Flow
-37.16M	-32.76M	-22.83M	-24.46M	-16.90M
	Operating Cash Flow
-37.07M	-32.69M	-22.18M	-23.94M	-16.70M
	Investing Cash Flow
-84.00K	-32.00K	-653.84K	-525.36K	-199.92K
	Financing Cash Flow
42.32M	38.61M	21.20M	19.39M	25.06M

Elicio Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTX, the sentiment is Neutral. The current price of 5.52 is above the 20-day moving average (MA) of 5.08, below the 50-day MA of 6.37, and below the 200-day MA of 5.70, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 49.77 is Neutral, neither overbought nor oversold. The STOCH value of 52.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ELTX.

Elicio Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.21B	3.49	-43.30%	2.83%	14.70%	-0.24%
SRZN	43 Neutral	$70.93M	―	-456.32%	―	―	0.13%
VTYX	41 Neutral	$88.24M	―	-46.04%	―	―	39.58%
JBIO	39 Underperform	$276.58M	―	-59.01%	―	―	44.04%
TNYA	36 Underperform	$67.33M	―	-76.21%	―	―	23.55%
BDTX	33 Underperform	$92.95M	―	4.14%	―	―	33.97%
ELTX	30 Underperform	$87.58M	―	-9999.00%	―	―	27.65%

Elicio Therapeutics Corporate Events

Elicio Therapeutics Appoints New Chief Strategy and Financial Officer

On March 21, 2025, Elicio Therapeutics appointed Preetam Shah, Ph.D., M.B.A., as Chief Strategy and Financial Officer, effective March 24, 2025. Dr. Shah’s extensive experience in corporate finance and strategy is expected to be a significant asset as Elicio advances its immunotherapy platform and prepares for key clinical milestones. His appointment comes at a crucial time for the company, which is focusing on the development of its lead product candidate, ELI-002, and other cancer vaccines. This strategic leadership change is anticipated to bolster Elicio’s efforts in aligning financial and corporate strategies with its goal of delivering cutting-edge cancer immunotherapeutics.